Orchestra BioMed Holdings, Inc.
OBIO
Rank in Stocks
#14145
Orchestra BioMed Holdings, Inc. operates as an innovative company in the... Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Share Price
$5.70
Last synced: 2026-11-09
Market Cap
$342.60M
Change (1 day)
0.35%
Change (1 year)
39.02%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orchestra BioMed Holdings, Inc. (OBIO)
Category
Healthcare
Operating Margin for Orchestra BioMed Holdings, Inc. (OBIO)
Operating Margin as of November 2026 TTM: -181.36%
According to Orchestra BioMed Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is -181.36%. At the end of 2025 the company had an operating margin of -154.73%.
Operating Margin history for Orchestra BioMed Holdings, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -181.36% | 17.21% |
| 2025 | -154.73% | -93.65% |
| 2024 | -2,437.49% | 30.62% |
| 2023 | -1,866.16% | 101.89% |
| 2022 | -924.34% | -133.16% |
| 2021 | 2,787.60% | -947.78% |
| 2020 | -328.81% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.21% |
US
|
|
| -149.01% | -99.18% |
US
|
|
| 25.57% | -100.14% |
AU
|
|
| 31.23% | -100.17% |
BE
|
|
| 29.35% | -100.16% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Orchestra BioMed Holdings, Inc.'s operating margin
What is Orchestra BioMed Holdings, Inc.'s operating margin?
Orchestra BioMed Holdings, Inc.'s operating margin is -181.36%, as of Nov 2026.
What was Orchestra BioMed Holdings, Inc.'s operating margin in 2025?
In 2025, Orchestra BioMed Holdings, Inc.'s operating margin was -154.73%, compared with -2,437.49% in 2024.
How has Orchestra BioMed Holdings, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Orchestra BioMed Holdings, Inc.'s operating margin was highest in 2021 (2,787.60%) and lowest in 2024 (-2,437.49%).
How does Orchestra BioMed Holdings, Inc.'s operating margin compare with similar companies?
Orchestra BioMed Holdings, Inc.'s operating margin (-181.36%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.